SpainSpain

Gardasil vaccinations to continue

26.02.2009

Madrid - The distribution of cervical cancer vaccine Gardasil in Spain is likely to recommence soon. The European Medicines Agency (EMEA) has reviewed the available information on the two cases of status epilepticus with myoclonus (repeated and prolonged seizures and loss of consciousness) reported in two girls vaccinated with Gardasil in Spain. Based on the current data, the Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the cases are unlikely to be related to vaccination with the substance, and that the benefits of Gardasil continue to outweigh its risks. The Committee is therefore recommending that vaccinations should continue in accordance with national vaccination programmes in Member States. Both girls were vaccinated with the same batch of Gardasil, became ill shortly after vaccination, and are now improving. Following the two cases, the Spanish public health authorities in early February took the precautionary measure of halting vaccination with the batch of Gardasil concerned. The Italian authorities stopped vaccination with the batch shortly thereafter, and the distribution of the entire batch was stopped a day later. The CHMP and its Pharmacovigilance Working Party are continuing to investigate the situation. The marketing authorisation holder has been asked to provide a full analysis of the batch, as well as further information on the vaccine's side effects, any similar cases, and possible ways in which Gardasil could be linked to the cases seen in Spain. Following assessment of all available data, the CHMP will determine whether further action is necessary. The Committee recommended an update of the Product Information for Gardasil in January to emphasize information on syncope (fainting) as a possible side effect of vaccination with the substance.

SpainSpain

01.10.2011

Granada – Alentia Biotech, a joint venture of Grupo Ferrer Internacional S.A. and Laboratorios Farmacéuticos Rovi S.A, has announced plans to construct a national production centre to supply the Spanish population with flu...

SpainSpain

01.10.2011

Lisbon – A Portuguese-American research team has discovered an association between a variant in the gene DZIP1 and Parkinson’s disease (PD). The collaboration brought André Valente from the Biocant Biotechnology Innovation Center...

SpainSpain

29.09.2011

Granada - Alentia Biotech, a joint venture of Spanish pharmaceuticals companies Laboratorios Farmaceuticos Rovi SA and Ferrer, will invest €92m in the construction of a flu vaccines plant in Granada. The annual production...

SpainSpain

23.09.2011

Madrid - Spain unveiled a grand alliance between all stakeholders in biomedicine to foster innovation in the sector. Minister of Science and Innovation, Cristina Garmendia, met the representatives of institutions, public research...

Italy, SpainSpain

18.08.2011

Vinaros – The Italian company Transactiva failed to start a field trial of a genetically modified rice variant in southeastern Spain. Although the National Commission on Biosafety had approved the field trial, the Committee on...

SpainSpain

09.08.2011

Madrid/Ingelheim – Pharmaceutical company Boehringer Ingelheim has cleared the way for Spanish rival Almirall and ended a long-standing patent squabble, although the reconciliation was not exactly voluntary. Behind the scenes,...

SpainSpain

13.06.2011

Madrid – Spain is working to establish itself as a European hotspot for bio­energy production. The country’s Abengoa Bioenergia Nuevas Tecnologias, a subsidiary of Abengoa Bioenergy, will lead an international consortium in the...

SpainSpain

11.06.2011

Madrid – Agendas, working committees and associations in Europe’s biotechnology sector are not hard to find. Now the spanking new Spanish Biotech Platform (launched in May) has to show if it is more than just another extension of...

SpainSpain

06.02.2011

Madrid – Noscira, a Madrid-based company looking for Alzheimer treatments in marine life forms, raised a19m in a private placement of 3.8 million shares at EUR5 to existing and new investors. The main stakeholder is Zeltia S.A,...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/1/article/gardasil-vaccinations-to-continue.html

Product of the week

Products

Events

All Events

Current issue

All issues